Understanding Chronic Pain
Chronic pain affects an estimated 28 million adults in the United Kingdom, making it one of the most prevalent health conditions in the country. Unlike acute pain, chronic pain persists beyond the normal healing period, typically lasting more than three months. The economic burden on the NHS is estimated at £18.8 billion annually.
For a substantial proportion of patients, existing treatments — NSAIDs, opioids, anticonvulsants — fail to provide adequate relief. Medical cannabis is increasingly being considered as a complementary or alternative therapeutic option.
The Endocannabinoid System and Pain
The human body contains a widespread cell-signalling network known as the endocannabinoid system (ECS), which plays a central role in pain regulation. The ECS comprises endogenous cannabinoids (anandamide and 2-AG), their receptors (CB1, predominantly in the central nervous system; CB2, predominantly in peripheral tissues and immune cells), and the enzymes that synthesise and degrade them.
In chronic pain states, the ECS is often dysregulated. Exogenous cannabinoids — primarily THC and CBD — interact with this system to modulate pain transmission. THC acts as a partial agonist at CB1 receptors, reducing nociceptive signalling and altering pain perception. CBD contributes anti-inflammatory and analgesic effects without psychoactivity.
Clinical Evidence for Chronic Pain
A 2018 systematic review in JAMA Internal Medicine identified 47 randomised controlled trials involving 4,743 participants and found cannabinoids were associated with a greater average reduction in pain scores versus placebo. The National Academies of Sciences, Engineering, and Medicine concluded in 2017 that there is substantial evidence that cannabis is an effective treatment for chronic pain in adults.
UK-specific data from the Drug Science Medical Cannabis Registry demonstrates significant improvements in pain scores, sleep quality, and anxiety in patients prescribed cannabis-based medicines. A 2022 analysis found that 75% of UK chronic pain patients reported clinically meaningful improvements after six months of treatment.
Types of Chronic Pain
- Neuropathic pain — including diabetic neuropathy, post-herpetic neuralgia, and chemotherapy-induced peripheral neuropathy
- Musculoskeletal pain — persistent back pain, joint pain not amenable to surgical intervention
- Central sensitisation conditions — fibromyalgia, complex regional pain syndrome (CRPS)
- Cancer-related pain — both disease-related and treatment-related
EU-GMP Certified Products
Cannamedical Britannia sources exclusively from EU-GMP certified cultivation and manufacturing facilities across Germany, Portugal, and Denmark. Every batch is independently tested for cannabinoid potency, terpene profile, residual solvents, heavy metals, pesticides, and microbial contamination. For chronic pain patients, high-THC flower varieties offer rapid onset for breakthrough pain, while balanced THC:CBD oils and capsules provide sustained baseline relief.
The UK Prescribing Pathway
- Initial consultation — A GMC-registered specialist reviews your full medical history, current medications, and prior treatments.
- Eligibility assessment — The specialist determines whether you meet criteria, including a minimum of two prior treatments that have failed.
- Prescription and dispensing — If approved, a Schedule 2 controlled drug prescription is issued, fulfilled by a licensed UK pharmacy.
- Titration and monitoring — Dosing begins at low levels and gradually increases under specialist supervision.